ORLANDO, Fla.--(EON: Enhanced Online News)--Coming together with thousands of leading clinicians who treat patients with chronic pain, NeuroMetrix, Inc. (Nasdaq: NURO) will exhibit Quell®, its FDA-cleared, 100% drug-free wearable designed to provide widespread relief from chronic pain, at the American Academy of Pain Medicine (AAPM) 33rd Annual Meeting in Orlando, Fla., March 15-19, 2017 at booth #418.
“Quell empowers those living with chronic pain to reclaim their life through advanced technology. We’re looking forward to connecting with leading pain clinicians at this year’s meeting to bring more awareness to technological alternatives that can be shared with their patients.”
The theme of this year’s AAPM annual meeting is “Pain as a Public Health Issue,” and will cover educational content around the pressing need for pain clinicians to address this major public health burden through evidence-based treatments in practice. With nearly 100 million Americans living with chronic pain, and an estimated $635 billion spent a year on chronic pain management, NeuroMetrix is dedicated to meaningful innovation and bringing relief to those living with chronic pain with the latest technology.
“For one in three Americans, chronic pain continues to disrupt their everyday life, and they are continually looking to their clinicians for alternative treatments to alleviate their pain,” said Shai N. Gozani, M.D., Ph.D. “Quell empowers those living with chronic pain to reclaim their life through advanced technology. We’re looking forward to connecting with leading pain clinicians at this year’s meeting to bring more awareness to technological alternatives that can be shared with their patients.”
Quell combines advanced neurotechnology in a wearable format with a sophisticated app for users to personalize and control therapy, while tracking their pain and relevant health metrics. The product has made a difference in tens of thousands of lives since its introduction in 2015. In a clinical study published last year in the Journal of Pain Research, 81 percent of subjects reported improvement in their chronic pain, and 67 percent reported a reduction in their use of pain medication after 60 days of using Quell.
The AAPM 33rd Annual Meeting will be held March 15-19, 2017 at the Loews Sapphire Falls Resort at Universal Orlando in Orlando, Fla. Attendees can learn more about Quell by visiting the NeuroMetrix booth, #418 during the conference and following along on Twitter @Quellrelief.
Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can personalize and manage therapy discreetly via the Quell Relief app. Quell also offers advanced health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.
NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.